Darwin Biosciences Inc.
The University of Colorado Connection
Darwin specializes in saliva-based diagnostics for the early detection of infectious diseases by translating signals in human saliva derived from the earliest immune response using a portable, hand-held device. Darwin was founded on technology developed in the laboratory of Sara Sawyer (CU Boulder Molecular, Cellular & Developmental Biology, BioFrontiers Institute).
Funding Status and Investment Opportunities
- Industry Applications: Biotech, Diagnostics
- Funding Stage: Seed Round
- Contact for Investment Inquiries: Nick Myerson , nick@darwin.bio
In the News
- CU Boulder hosts showcases highlighting breakthrough innovations and investment-ready ventures (2025)
- Six CU Boulder startups selected to present at the Rocky Mountain Life Science Investor Conference (2024)
- Turning science into startups (2023)
- As pandemic spread, ‘I couldn’t just sit around’ (2022)
- Darwin Biosciences named a 2022 Colorado Company to Watch (2022)
- CU Boulder’s bottom-up approach to innovation drives economic development (APLU, 2021)
- Scientists developing COVID-19 test that knows you’re sick before you do (2020)
- New CU Boulder COVID-19 test (2020)
Venture Partners Programs
This technology was developed with funding from
U.S. Department of Defense, U.S. Defense Threat Reduction Agency (DTRA), U.S. National Institutes of Health (NIH)
This page was last updated on April 3, 2025. Please email vpnews@colorado.edu for corrections or updates
The Insider Investor E-Newsletter
Media Inquiries
For marketing and communication inquiries, contact Daniel Leonard, senior marketing and communications specialist for Venture Partners at CU Boulder.
For media inquiries, please visit colorado.edu/news/formedia.